{"id":"NCT02425111","sponsor":"Takeda","briefTitle":"Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease","officialTitle":"An Open-Label Phase 3b Study to Assess Mucosal Healing in Subjects With Moderately to Severely Active Crohn's Disease Treated With Vedolizumab IV","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-03-30","primaryCompletion":"2017-06-02","completion":"2018-02-21","firstPosted":"2015-04-23","resultsPosted":"2018-09-14","lastUpdate":"2018-09-14"},"enrollment":101,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease"],"interventions":[{"type":"DRUG","name":"Vedolizumab","otherNames":["MLN0002"]}],"arms":[{"label":"Vedolizumab 300 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate endoscopic remission at Week 26 as assessed by ileocolonoscopy.","primaryOutcome":{"measure":"Part A: Percentage of Participants Achieving Endoscopic Remission at Week 26","timeFrame":"Week 26","effectByArm":[{"arm":"Vedolizumab 300 mg","deltaMin":11.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":79,"countries":["United States","Belgium","Canada","Czechia","France","Hungary","Italy","Poland"]},"refs":{"pmids":["38298861","35435862","31279871"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":101},"commonTop":["Crohn's disease","Viral upper respiratory tract infection","Abdominal pain","Headache","Nausea"]}}